Azitra is trading at $0.14, up 5.91%, with no specific company announcement identified to explain the October 5 move.
- The latest company news found was an October 1 update that its ATR04-484 trial could proceed to Cohort 2 after a safety review.
- Broader markets were higher: the S&P 500 was up 0.76% and the Nasdaq was up 1.20%. The supportive backdrop may be relevant, but no direct link to Azitra’s gain is confirmed.